20 completed, 1 withdrawn. 11 Phase 2, 3 Phase 1, 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 10, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
| Not applicable | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Previously Treated Childhood Rhabdomyosarcoma: new trials by email Literature Review of Previously Treated Childhood Rhabdomyosarcoma trials Research Report on Previously Treated Childhood Rhabdomyosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Imetelstat Sodium, Laboratory Biomarker Analysis - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma | Phase 2 | Withdrawn | Children's Oncology Group | 2014-06-30 | 2018-08-07 | |
| Biomarkers in Patients With Advanced Rhabdomyosarcoma Laboratory Biomarker Analysis - Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma | Completed | Children's Oncology Group | 10 | 2012-08-01 | 2016-05-18 | |
| Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 46 | 2012-06-18 | 2018-12-11 |
| Studying Mechanisms of Radiation Therapy Resistance in Samples From Younger Patients With Rhabdomyosarcoma laboratory biomarker analysis - Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma | Completed | Children's Oncology Group | 20 | 2012-06-01 | 2016-07-14 | |
| Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma laboratory biomarker analysis - Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma | Completed | Children's Oncology Group | 99 | 2012-06-01 | 2016-05-18 | |
| Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer sorafenib tosylate, pharmacological study, laboratory biomarker analysis - Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2012-01-01 | 2018-06-26 |
| Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant supersaturated calcium phosphate rinse, placebo, questionnaire administration - Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission | Phase 3 | Completed | Children's Oncology Group | 226 | 2011-03-01 | 2019-09-17 |
| Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma | Phase 2 | Completed | Children's Oncology Group | 118 | 2011-02-01 | 2020-05-13 |
| Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases intensity-modulated radiation therapy - Adult Rhabdomyosarcoma, Lung Metastases | Not applicable | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 20 | 2011-02-01 | 2025-02-10 |
| Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis - Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 87 | 2010-10-01 | 2017-05-05 |
| Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors cixutumumab, laboratory biomarker analysis - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 116 | 2009-01-01 | 2015-03-30 |
| Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2008-06-01 | 2016-05-17 |
| Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors trabectedin, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma | Phase 2 | Completed | Children's Oncology Group | 50 | 2008-01-01 | 2018-09-14 |
| Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant lithium carbonate, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Completed | Fred Hutchinson Cancer Center | 20 | 2006-06-01 | 2017-03-07 |
| Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant etanercept, methylprednisolone - Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia | Phase 2 | Completed | Children's Oncology Group | 39 | 2006-04-01 | 2017-09-29 |
| Ixabepilone in Treating Young Patients With Refractory Solid Tumors ixabepilone - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 120 | 2006-04-01 | 2014-11-14 |
| Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors tanespimycin, pharmacological study, laboratory biomarker analysis - Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 70 | 2004-09-01 | 2013-06-04 |
| Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors erlotinib hydrochloride, temozolomide, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 95 | 2004-02-01 | 2013-06-05 |
| Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma vincristine sulfate, irinotecan hydrochloride, cyclophosphamide - Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 150 | 2001-11-01 | 2013-01-17 |
| Irinotecan in Treating Children With Refractory Solid Tumors irinotecan hydrochloride - Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor | Phase 2 | Completed | Children's Oncology Group | 181 | 1999-10-01 | 2013-06-14 |
Showing 20 of 21. Sign in to see all of them.
Neuroblastoma (9) · Rhabdomyosarcoma (9) · Osteosarcoma (8) · Sarcoma (8) · Neuroectodermal Tumors, Primitive, Peripheral (7) · Wilms Tumor (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Burkitt Lymphoma (3) · Dendritic Cell Sarcoma, Interdigitating (3) · Desmoplastic Small Round Cell Tumor (3) · Hepatoblastoma (3) · Leukemia, Myelomonocytic, Juvenile (3) · Recurrence (3) · Sarcoma, Ewing (3) · Sarcoma, Synovial (3)
Neoplasms (18) · Neoplasms by Histologic Type (18) · Neoplasms, Connective and Soft Tissue (14) · Neoplasms, Connective Tissue (12) · Neoplasms, Germ Cell and Embryonal (12) · Neoplasms, Glandular and Epithelial (12) · Neoplasms, Nerve Tissue (12) · Neoplasms, Neuroepithelial (11) · Neuroectodermal Tumors, Primitive (11) · Neoplasms, Bone Tissue (10) · Neuroectodermal Tumors (10) · Myosarcoma (9) · Neoplasms, Complex and Mixed (9) · Neoplasms, Muscle Tissue (9) · Neoplasms by Site (8)
cixutumumab (3) · Cyclophosphamide (2) · Doxorubicin (2) · Irinotecan (2) · Sirolimus (2) · temsirolimus (2) · Bevacizumab (1) · Disulfides (1) · Erlotinib Hydrochloride (1) · Etanercept (1) · Etoposide (1) · Filgrastim (1) · GRN163L peptide (1) · Granulocyte Colony-Stimulating Factor (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1)
Children's Oncology Group (10) · National Cancer Institute (NCI) (9) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Fred Hutchinson Cancer Center (1)
United States (20) · Canada (8) · Australia (5) · New Zealand (2) · Netherlands (1) · Puerto Rico (1) · Switzerland (1)
AeRang Kim, MD (1) · Brenda Weigel, MD (1) · Brigitte Widemann (1) · Charles Keller, MD (1) · Christopher Pelloski, MD (1) · David Walterhouse (1) · Frederick Barr, MD (1) · Gregory Yanik, MD (1) · Lars Wagner (1) · Leo Mascarenhas (1) · Lisa Bomgaars (1) · Nathaniel Treister, MD (1) · Patrick Thompson (1) · Paul Martin (1) · Philip Breitfeld (1)
PMID 22088484, PMID 25858498, PMID 28817727, PMID 30777875, PMID 31513481, PMID 34435684
U10CA098543 (11), N01CM00071 (1), P30CA014599 (1), R21CA159547 (1), U01CA069856 (1), U01CA097452 (1), U10CA024507 (1), U10CA095861 (1), UG1CA189958 (1)